ArticleGene therapy2008
IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 93 citations in OpenAlex.
- Extracellular Vesicle-Associated IL4 Displays Enhanced Anti-Inflammatory Properties in Microglial Cells.Journal of extracellular biology · 2026Article
- Mechanisms of T cell activation: Integrating signaling pathways, experimental models, and therapeutic implications.EXCLI journal · 2026Review
- Effects of Balanced Supplementation with Multiple Trace Elements on Oxidative Stress, Inflammation, and Immune Function in High-Fat Diet-Induced Rats.International journal of preventive medicine · 2025Article
- Role of microglia/macrophage polarisation in intraocular diseases (Review).International journal of molecular medicine · 2024Review
- The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.Frontiers in immunology · 2024Article
- The Role of the Intestinal Microbiome in Multiple Sclerosis-Lessons to Be Learned from Hippocrates.Biology · 2023Review
- Targeted adenovirus-mediated transduction of human T cellsMolecular therapy. Methods & clinical development · 2023Article
- Intranasal administration of interleukin-4 ameliorates depression-like behavior and biochemical alterations in mouse submitted to the chronic unpredictable mild stress: modulation of neuroinflammation and oxidative stress.Psychopharmacology · 2023Article
- Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis.Frontiers in immunology · 2023Article
- Article
- Interleukin-4 receptor signaling modulates neuronal network activity.The Journal of experimental medicine · 2022Article
- Cutting Edge: DOCK8 Regulates a Subset of Dendritic Cells That Is Critical for the Development of Experimental Autoimmune Encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- A review of possible therapies for multiple sclerosis.Molecular and cellular biochemistry · 2021Review
- Interleukin-4 Improves Metabolic Abnormalities in Leptin-Deficient and High-Fat Diet Mice.International journal of molecular sciences · 2020Article
- Alternatively activated macrophages; a double-edged sword in allergic asthma.Journal of translational medicine · 2020Review
- Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long-lasting stability.Journal of nanobiotechnology · 2019Article
- LFA-1 Controls Th1 and Th17 Motility Behavior in the Inflamed Central Nervous System.Frontiers in immunology · 2019Article
- CD45Rb-low effector T cells require IL-4 to induce IL-10 in FoxP3 Tregs and to protect mice from inflammation.PloS one · 2019Article
- Further Evidence on Efficacy of Diet Supplementation with Fatty Acids in Ocular Pathologies: Insights from the EAE Model of Optic Neuritis.Nutrients · 2018Article
- Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.Cancer discovery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) delivery of anti-inflammatory cytokines, such as interleukin 4 (IL4), holds promise as treatment for multiple sclerosis (MS). We have previously shown that short-term herpes simplex virus type 1-mediated IL4 gene therapy is able to inhibit experimental autoimmune encephalomyelitis (EAE), an animal model of MS, in mice and non-human primates. Here, we show that a single administration of an IL4-expressing helper-dependent adenoviral vector (HD-Ad) into the cerebrospinal fluid (CSF) circulation of immunocompetent mice allows persistent transduction of neuroepithelial cells and long-term (up to 5 months) CNS transgene expression without toxicity. Mice affected by chronic and relapsing EAE display clinical and neurophysiological recovery from the disease once injected with the IL4-expressing HD-Ad vector. The therapeutic effect is due to the ability of IL4 to increase, in inflamed CNS areas, chemokines (CCL1, CCL17 and CCL22) capable of recruiting regulatory T cells (CD4+CD69-CD25+Foxp3+) with suppressant functions. CSF delivery of HD-Ad vectors expressing anti-inflammatory molecules might represent a valuable therapeutic option for CNS inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.